Cargando…

Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease

Detalles Bibliográficos
Autores principales:	Kupryś-Lipińska, Izabela, Pałczyński, Cezary, Molinska, Joanna, Kuna, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627253/ https://www.ncbi.nlm.nih.gov/pubmed/31320863 http://dx.doi.org/10.5114/ada.2018.73140

Ejemplares similares

Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2016)

Good outcomes of pregnancy in two cases of women treated with omalizumab due to the severe asthma
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2013)

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2015)

Loss of asthma control after cessation of omalizumab treatment: real life data
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Prevalence, risk factors and underdiagnosis of asthma in the general population aged over 60 years
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2019)

The position paper of the Polish Society of Allergology on climate changes, natural disasters and allergy and asthma
por: Pałczyński, Cezary, et al.
Publicado: (2018)

Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2020)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Effectiveness and adverse events of plasmapheresis and immunoglobulin G infusion in patient with resistant chronic urticaria and angioedema - a case report
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2015)

COVID‐19 in a patient with severe asthma treated with Omalizumab
por: Lommatzsch, Marek, et al.
Publicado: (2020)

Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma
por: Kupczyk, Maciej, et al.
Publicado: (2019)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland
por: Stelmach, Iwona, et al.
Publicado: (2015)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

High levels of anxiety during the COVID-19 pandemic as a risk factor of clinical worsening in patients with severe asthma
por: Lacwik, Piotr, et al.
Publicado: (2021)

287 Nasal Nitric Oxide Levels after Lysine Aspirin Nasal Challenge in Subjects with Aspirin Induced Asthma
por: Tworek, Damian, et al.
Publicado: (2012)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Expression of cPLA(2)γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen
por: Pniewska-Dawidczyk, Ewa, et al.
Publicado: (2021)

Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases
por: Fiorino, Irene, et al.
Publicado: (2014)

Asthma-chronic obstructive pulmonary disease overlap syndrome: Is prediction feasible?
por: Karim, Habi Md Reazaul, et al.
Publicado: (2018)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Adults with asthma treated with add-on omalizumab report less limitation in activities of daily living
por: de Oliveira, Joice Mara, et al.
Publicado: (2022)

Reply to: Asthma-chronic obstructive pulmonary disease overlap syndrome: Is prediction feasible?
por: Ayub, Irfan Ismail, et al.
Publicado: (2018)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps
por: Pietruszewska, Wioletta, et al.
Publicado: (2021)

Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study
por: Carraro, Silvia, et al.
Publicado: (2022)

The Step Further to Understand the Role of Cytosolic Phospholipase A(2) Alpha and Group X Secretory Phospholipase A(2) in Allergic Inflammation: Pilot Study
por: Pniewska, Ewa, et al.
Publicado: (2014)

Assessment of asthma and chronic obstructive pulmonary disorder
por: Wiwanitkit, Viroj
Publicado: (2011)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab as a new therapeutic approach for children with severe asthma
por: Jerzyńska, Joanna, et al.
Publicado: (2014)

Efficacy of omalizumab in reducing latex allergy
por: Aruanno, Arianna, et al.
Publicado: (2021)

The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria – a pilot study
por: Korczyñska-Krawczyk, Paulina, et al.
Publicado: (2018)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
por: Prætorius, Katrine, et al.
Publicado: (2021)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
por: Solidoro, Paolo, et al.
Publicado: (2019)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

Age of asthma onset does not impact the response to omalizumab
por: Rogers, Linda, et al.
Publicado: (2023)

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
por: Lefévre, Anna Cecilie, et al.
Publicado: (2013)

Omalizumab as a Provoking Factor for Venous Thromboembolism
por: Oblitas, Crhistian-Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rt1c1ceuh41dde85g65t4mdctr